Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The impact of protein therapeutics in healthcare is steadily increasing, due to advancements in the field of biotechnology and a deeper understanding of several pathologies. However, their safety and efficacy are often limited by instability, short half-life and immunogenicity. Nanodelivery systems are currently being investigated for overcoming these limitations and include covalent attachment of biocompatible polymers (PEG and other synthetic or naturally derived macromolecules) as well as protein nanoencapsulation in colloidal systems (liposomes and other lipid or polymeric nanocarriers). Such strategies have the potential to develop next-generation protein therapeutics. Herein, we review recent research progresses on these nanodelivery approaches, as well as future directions and challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Liposomes represent the first nanosized drug delivery system which made the transition from bench to clinical application, and provide ideal characteristics of biocompatibility, biodegradability, variable compositions (Allen and Cullis, 2013; Sercombe et al., 2015).”
BackgroundPoly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“…the hydrophobic transmembrane region, depending on the nature of the proteins and the lipids involved, which are capable of forming electrostatic and hydrophobic interactions, hydrogen bonds, due to the polar and hydrophobic groups present in their complex structure (Lee, 2004; McClements, 2018).”
BackgroundNew-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600 · cited 3×
“The HESylation of erythropoietin (EPO) had comparable in vitro and in vivo activities to PEGylated-EPO (Mircera) (Hey et al., 2012; Pelegri-O’Day et al., 2014).”
BackgroundBiopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · cited 3×
“Over the last few years, several therapeutic proteins have been approved for clinical usage, and others are in the process of development (Leader et al., 2008; Walsh, 2018).”
BackgroundTurecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
Pelegri-O’Day, E. M., Lin, E.-W., & Maynard, H. D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504390x · Cited by 622
Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · doi:10.20944/preprints201810.0507.v1 · Cited by 605
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593 · cited 2×
“In these models, chain length, conformation and grafting density are important factors for limiting protein binding (Yang and Lai, 2015).”
BackgroundRecent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Yarosh, D., Klein, J., O'Connor, A., Hawk, J., Rafal, E., & Wolf, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04214-8 · Cited by 390 · cited 1×
“Among their advantages, liposomal formulations can be administered through several different routes such as parenteral (the most studied), oral (He et al., 2019), pulmonary (Khanna et al., 1997b), nasal (Luo et al., 2018), ocular (Agarwal et al., 2016), and topical (Yarosh et al., 2001).”
BackgroundTan, M. L., Choong, P. F. M., & Dass, C. R. (2010) · Peptides · doi:10.1016/j.peptides.2009.10.002 · Cited by 350
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s
Gaertner, F. C., Luxenhofer, R., Blechert, B., Jordan, R., & Essler, M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.015 · Cited by 255
Role of the methoxy group in immune responses to mPEG-protein conjugates
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200551b · Cited by 185
Rudmann, D. G., Alston, J. T., Hanson, J. C., & Heidel, S. (2013) · Toxicologic Pathology · doi:10.1177/0192623312474726 · Cited by 170
Oral delivery of peptides and proteins using lipid-based drug delivery systems
Li, P., Nielsen, H. M., & Müllertz, A. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.717068 · Cited by 116 · cited 1×
“Furthermore HESylation R© sharply improved the storage stability over PEGylation by remaining totally amorphous during lyophilisation, with and without lyoprotectants (Liebner et al., 2015).”
BackgroundLuo, J., Yang, Y., Zhang, T., Su, Z., Yu, D., Lin, Q., Chen, H., Zhang, Q., Xiang, Q., Xue, W., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.021 · Cited by 42
Cited by
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., et al. (2020) · Molecules · doi:10.3390/molecules25163731 · Cited by 1,560
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Rivera, K. O., Cuylear, D. L., Duke, V. R., O’Hara, K. M., Zhong, J. X., Elghazali, N. A., Finbloom, J. A., Kharbikar, B. N., Kryger, A. N., Miclau, T., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190371 · Cited by 22
Polymers for the treatment of Alzheimer’s disease
Zhu, Y., Xu, H., Yu, C., Jiang, W., Hou, X., Ma, M., & Wu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1512941 · Cited by 5
Maharaja Agrasen Himalayan Garhwal University, P., Kumar, P., Goel, A., Maharaja Agrasen Himalayan Garhwal University, P., Dash, B., Amity Institute of Pharmacy, A. U., Rishishwar, P., Maharaja Agrasen Himalayan Garhwal University, P., S, J., Alpha Pharma Industries, K. 2., et al. (2025) · Chinese Journal of Applied Physiology · doi:10.62958/j.cjap.2025.001 · Cited by 6
Metadata
- Authors
- Moncalvo, F., Martinez Espinoza, M. I., & Cellesi, F.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-14
- Volume
- 8
- Pages
- 89-89
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W3005961874
- Cited by
- 105
- References
- 22
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.